CARMAT is a medtech company, offering biocompatible, auto-regulated total artificial hearts as close as possible to the human heart.
CARMAT has raised €85M across 4 funding rounds from 1 investor, most recently a round in Apr 2022. Based in Vélizy-Villacoublay, France; founded 2008; active in AI and Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors |
|---|
| 2022-04-12 | Other | €41M | — | View deal → |
| 2021-03-09 | Other | €1.4M | — | View deal → |
| 2020-10-12 | Other | €13M | — | View deal → |
| 2018-12-17 | Other | €30M | European Investment Bank (EIB) | View deal → |
